Cynosure Inc (CYNO) 10-K Annual Report March 2015


Contact:

Timothy Baker		Scott Solomon
President and Chief Financial Officer		Vice President
Cynosure, Inc.		Sharon Merrill Associates
(978) 256-4200		(617) 542-5300
TBaker@cynosure.com		CYNO@investorrelations.com

Cynosure Reports Record Quarterly Revenue of $86.3 Million for the Fourth Quarter of 2014

Westford, MA – February 10, 2015

– Cynosure, Inc. (Nasdaq: CYNO), which designs, manufactures and markets medical devices for aesthetic procedures and precision surgical applications worldwide, today reported financial results for the three and 12 months ended December 31, 2014.

Financial Highlights

•

Q4 revenue up 16 percent year-over-year to $86.3 million

•

Q4 GAAP net income of $23.0 million, or $1.05 per diluted share, reflecting the release of income tax valuation allowance

•

Q4 non-GAAP net income of $7.9 million, or $0.36 per diluted share, excluding the release of income tax valuation allowance, acquisition costs and amortization expenses

•

Q4 cash from operations of $22.2 million; $133.4 million in cash and investments at December 31, 2014

•

Full-year 2014 revenue of $292.4 million, up 29 percent

“We capped an outstanding year in 2014 with a solid fourth quarter, driven by record revenues and continued profitability,” said Cynosure Chairman and Chief Executive Officer Michael Davin. “Equally important, we continue to generate strong operating cash flow and strengthen our balance sheet, while at the same time stepping up R&D and marketing investments as we focus on accelerating the pace at which our products are coming to market.”

The following information was filed by Cynosure Inc (CYNO) on Tuesday, February 10, 2015 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

Please wait while we load the requested 10-K report or click the link below:

https://last10k.com/sec-filings/report/885306/000119312515091339/d849220d10k.htm

View differences made from one year to another to evaluate Cynosure Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ) — *Sample 10-K Year-over-Year (YoY) Comparison*

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were ~~removed~~ , added and changed by Cynosure Inc.

Continue

Assess how Cynosure Inc's management team is paid from their Annual Proxy

Cynosure Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2015 10-K Annual Report includes:

Voting Procedures
Board Members
Executive Team
Salaries, Bonuses, Perks
Peers / Competitors

Continue

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Material Contracts, Statements, Certifications & more

Cynosure Inc provided additional information to their SEC Filing as exhibits

Exhibit 10.10: Material Contract

Exhibit 10.16: Material Contract

Exhibit 10.21: Material Contract

Exhibit 21.1: Subsidaries Of The Registrant

Exhibit 23.1: Consents Of Experts And Counsel

Exhibit 31.1: Rule 13A-14(A)/15D-14(A) Certification

Exhibit 31.2: Rule 13A-14(A)/15D-14(A) Certification

Exhibit 32.1: Section 1350 Certification

Exhibit 32.2: Section 1350 Certification

Ticker: CYNO
CIK: 885306
Form Type: 10-K Annual Report
Accession Number: 0001193125-15-091339
Submitted to the SEC: Fri Mar 13 2015 4:50:13 PM EST
Accepted by the SEC: Fri Mar 13 2015
Period: Wednesday, December 31, 2014
Industry: Electromedical And Electrotherapeutic Apparatus